Last updated: 2026-09-22 22:26:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Seaport Therapeutics, Inc. (SPTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $22.47, with a market capitalization of $1.15B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $14.85 to $28.38. This page covers its latest market performance, valuation, price trends and company information.
$1.15B | |
$21.20 | |
$28.38 | |
$14.85 | |
$21.12 | |
120.57K | |
176.51K | |
-- | |
$28.38 | |
$14.85 | |
-- | |
-- |
Seaport Therapeutics, Inc. (SPTX) is trading at $22.46 in after-hours trading as of 2026-09-22 20:55:00, up 6.34% ($1.34) from the regular-session close of $21.12.
After-hours trading shows how investors are pricing SPTX after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Seaport Therapeutics, Inc. (SPTX) moved from $23.34 to $22.47, representing a decline of 3.74% ($0.87).
The stock traded between $20.28 and $25.37 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 474.51 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 56.3%
SPTX is currently trading at $22.47, placing it 56.3% of the way from its 52-week low of $14.85 to its 52-week high of $28.38. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Seaport Therapeutics, Inc. (SPTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.